Deleted Journal,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 11
Published: Oct. 8, 2024
Diabetes
mellitus
(DM)
is
a
very
prevalent
chronic
disease
worldwide,
including
in
Portugal,
and
it
accompanied
by
significant
morbidity
mortality.
People
with
DM
must
follow
the
National
Vaccination
Program.
Additionally,
Portuguese
Society
of
Endocrinology,
Diabetes,
Metabolism
(Sociedade
Portuguesa
de
Endocrinologia,
e
Metabolismo,
SPEDM)
has
drawn
up
position
statement
to
promote
speed
relevant
vaccination
coverage
people
thus
prevent
infections
reduce
impact
such
diseases
on
population
at
increased
risk.
This
includes
against
Streptococcus
pneumoniae,
influenza,
severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2)/coronavirus
disease-2019
(COVID-19),
syncytial
virus
(RSV),
herpes
zoster
(HZ),
refers
adult
outside
context
pregnancy.
In
agreement
Directorate-General
Health
(Direcção-Geral
da
Saúde,
DGS),
2020,
SPEDM
recommended
immunization
13-valent
pneumococcal
polysaccharide
conjugate
vaccine
(PCV13)
23-valent
(PPV23)
adults
due
risk
invasive
disease.
Currently,
as
two
more
recent
vaccines
are
available,
preferentially
recommends,
this
population,
use
20-valent
(PCV20)
or,
an
alternative,
15-valent
(PCV15)
followed,
interval
12
months,
PPV23.
Annual
influenza
should
be
carried
out
accordance
DGS
norms
force;
among
groups
greatest
clinical
risk,
regardless
age.
SPEDM,
DGS,
also
recommends
SARS-CoV-2
DM,
following
proposed
schedules.
Considering
hospitalization
RSV
infection
for
aged
60
or
older,
especially
if
other
factors
coexist.
Finally,
given
greater
susceptibility
developing
HZ
its
complications,
50
years
well
18
older
immune
compromise,
factors,
personal
history
HZ.
changing
nature
epidemiological
context,
will
periodically
reviewed.
Clinical Infectious Diseases,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 23, 2024
Abstract
This
article
provides
a
focused
update
to
the
clinical
practice
guideline
on
treatment
and
management
of
patients
with
coronavirus
disease
2019,
developed
by
Infectious
Diseases
Society
America.
The
panel
presents
recommendation
use
anti–severe
acute
respiratory
syndrome
2
neutralizing
antibody
pemivibart
as
pre-exposure
prophylaxis.
is
based
evidence
derived
from
systematic
review
adheres
standardized
methodology
for
rating
certainty
strength
according
GRADE
(Grading
Recommendations,
Assessment,
Development,
Evaluation)
approach.
Information
included
in
U.S.
Food
Drug
Administration
Emergency
Use
Authorization
this
agent.
medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 13, 2024
ABSTRACT
Background
Pemivibart
received
emergency-use
authorization
for
prevention
of
symptomatic
COVID-19
in
moderate-to-severe
immunocompromised
individuals
based
on
immunobridging
analysis
the
phase
3
CANOPY
trial.
We
report
an
interim
safety
and
efficacy
pemivibart
with
(cohort
A)
or
without
B)
significant
immunocompromise
over
a
contemporary
variant
landscape.
Methods
Eligible
participants
(aged
≥18
years;
SARS-CoV-2-negative)
2
intravenous
4500-mg
infusions
blinded
placebo
(2:1,
cohort
90
days
apart.
Safety
was
primary
endpoint.
Composite
incidence
reverse
transcription-polymerase
chain
reaction
(RT-PCR)-confirmed
COVID-19,
hospitalization,
all-cause
mortality
evaluated
through
month
6
12
B).
Results
In
September-November
2023,
306
A;
317
162
B.
The
most
common
study
drug-related
adverse
event
infusion-related
reactions
A:
11/306
[3.6%];
B:
7/317
[2.2%,
pemivibart]
0/162
[placebo]).
Four
623
(0.6%)
who
experienced
anaphylactic
(2
non-serious;
serious)
within
24
hours
dosing.
A,
composite
endpoint
(day
180)
11/298
(3.7%;
deaths
[suicide
unknown
cause])
first
full
dose
pemivibart.
B,
6/317
(1.9%)
group
19/160
(11.9%)
group,
representing
84.1%
standardized
relative
risk
reduction
(RRR)
(95%
CI,
60.9-93.5;
nominal
P
<.0001)
Through
12,
15/317
(4.7%;
1
death
[cardiac
failure])
29/160
(18.1%)
met
clinical
endpoint,
respectively
demonstrating
73.9%
RRR
52.8-85.6;
<.0001).
Conclusions
provided
pre-exposure
prophylactic
against
well-tolerated
by
immunocompromise.
Anaphylaxis
important
risk.
Clinical
Trials
Registration
NCT06039449
Key
points
Pre-exposure
administration
doses
approximately
apart
generally
protection
months
Deleted Journal,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 11
Published: Oct. 8, 2024
Diabetes
mellitus
(DM)
is
a
very
prevalent
chronic
disease
worldwide,
including
in
Portugal,
and
it
accompanied
by
significant
morbidity
mortality.
People
with
DM
must
follow
the
National
Vaccination
Program.
Additionally,
Portuguese
Society
of
Endocrinology,
Diabetes,
Metabolism
(Sociedade
Portuguesa
de
Endocrinologia,
e
Metabolismo,
SPEDM)
has
drawn
up
position
statement
to
promote
speed
relevant
vaccination
coverage
people
thus
prevent
infections
reduce
impact
such
diseases
on
population
at
increased
risk.
This
includes
against
Streptococcus
pneumoniae,
influenza,
severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2)/coronavirus
disease-2019
(COVID-19),
syncytial
virus
(RSV),
herpes
zoster
(HZ),
refers
adult
outside
context
pregnancy.
In
agreement
Directorate-General
Health
(Direcção-Geral
da
Saúde,
DGS),
2020,
SPEDM
recommended
immunization
13-valent
pneumococcal
polysaccharide
conjugate
vaccine
(PCV13)
23-valent
(PPV23)
adults
due
risk
invasive
disease.
Currently,
as
two
more
recent
vaccines
are
available,
preferentially
recommends,
this
population,
use
20-valent
(PCV20)
or,
an
alternative,
15-valent
(PCV15)
followed,
interval
12
months,
PPV23.
Annual
influenza
should
be
carried
out
accordance
DGS
norms
force;
among
groups
greatest
clinical
risk,
regardless
age.
SPEDM,
DGS,
also
recommends
SARS-CoV-2
DM,
following
proposed
schedules.
Considering
hospitalization
RSV
infection
for
aged
60
or
older,
especially
if
other
factors
coexist.
Finally,
given
greater
susceptibility
developing
HZ
its
complications,
50
years
well
18
older
immune
compromise,
factors,
personal
history
HZ.
changing
nature
epidemiological
context,
will
periodically
reviewed.
